Journal article · 2025 · Open access
POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE
Annals of the Rheumatic Diseases, 84, 722 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.05.888
In brief
“POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE” is a 2025 journal article by M. Schaefer and 6 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.
- Citations
- 0
- Authors
- 7
Abstract
Background: Rheumatoid arthritis (RA) is associated with an increased risk for malignancies, with differences regarding specific cancer types [1]. Dealing with cancer and a chronic inflammatory disease at the same time is challenging for both patients and physicians. Based on the data available to date, the risk of new malignancies does not appear to be increased in RA patients with a history of malignancy treated with biological (b) disease-modifying anti-rheumatic drugs (DMARDs) compared to conventional synthetic (cs) DMARDs. There is some evidence that tumour necrosis factor inhibitors (TNFi) may have a lower malignancy risk than csDMARDs [2, 3]. However, for some of the DMARD therapies there are no data on cancer development after a previous cancer e.g. for Interleukin-6 inhibition (IL6i) or Janus Kinase inhibition (JAKi). Objectives: To estimate and compare the effects of JAKi, TNFi, abatacept (ABA), rituximab (RTX), IL6i and csDMARDs on the risk of new incident or recurrent malignancies in patients with RA and previous malignancy in routine care. Methods: Data from patients with a history of malignancies enrolled in the RABBIT register between 11/2006 and 12/2021 with the start of a DMARD treatment were analysed. Incidence rates (IR) of new incident or recurrent malignancies (without non-melanoma skin cancer) per 1000 patient-years (PY) with 95% confidence intervals (CI) were calculated. Relative risk was estimated as hazard ratios (HR) by Cox regression, adjusted by stabilized and winsorized inverse probability weights, taking into account age, sex, smoking, concomitant therapies with glucocorticoids and csDMARDs, disease duration, disease activity, number of prior DMARD therapies, rheumatoid factor/ACPA positivity and cancer-relevant comorbidities as covariates. A 6-month latency period after treatment start and multiple imputation of missing data were applied, events were assigned to therapies by the "once exposed, always at risk" rule. Results: 118 JAKi, 278 TNFi, 87 ABA, 202 RTX, 104 IL6i and 413 csDMARD treatment episodes were documented from a total of 706 patients. JAKi patients were older on average and more frequently smokers than others, while patients receiving ABA, RTX and IL6i on average had a longer disease duration and were more frequently seropositive than other patients. Patients receiving ABA and RTX were more frequently enrolled in a clinic. Patients under TNFi were slightly more often male and had received considerably less prior DMARD therapies, particularly less TNFi and IL6i (Table 1). 127 malignancies were reported, with 14, 40, 9, 34, 17 and 70 occurring under JAKi, TNFi, ABA, RTX, IL6i and csDMARDs, respectively. IRs ranged from 23 to about 40 under csDMARDs and JAKi (Tble 2). However, when adjusted…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Schaefer, M., Wernitzsch, H., Blank, N., Müller, B., Manger, B., Regierer, A. C., & Strangfeld, A. (2025). POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE. Annals of the Rheumatic Diseases, 84, 722. https://doi.org/10.1016/j.ard.2025.05.888
MLA 9
Schaefer, M., et al. “POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE.” Annals of the Rheumatic Diseases, vol. 84, 2025, p. 722. https://doi.org/10.1016/j.ard.2025.05.888.
Chicago
Schaefer, M., H. Wernitzsch, N. Blank, B. Müller, Bernhard Manger, Anne C. Regierer, and Anja Strangfeld. 2025. “POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE.” Annals of the Rheumatic Diseases 84: 722. https://doi.org/10.1016/j.ard.2025.05.888.
Harvard
Schaefer, M. et al. (2025) ‘POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE’, Annals of the Rheumatic Diseases, 84, p. 722. doi:10.1016/j.ard.2025.05.888.
IEEE
M. Schaefer et al., “POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE,” Annals of the Rheumatic Diseases, vol. 84, p. 722, 2025, doi: 10.1016/j.ard.2025.05.888.
BibTeX
@article{schaefer2025incident,
title = {{POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE}},
author = {Schaefer, M. and Wernitzsch, H. and Blank, N. and Müller, B. and Manger, Bernhard and Regierer, Anne C. and Strangfeld, Anja},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
pages = {722},
doi = {10.1016/j.ard.2025.05.888},
url = {https://doi.org/10.1016/j.ard.2025.05.888}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- cancer risk
- tumor recurrence
- disease-modifying antirheumatic drugs
- JAK inhibitors
- tumor necrosis factor inhibitors
- abatacept
- rituximab
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Schaefer, M., Wernitzsch, H., Blank, N., Müller, B., Manger, B., Regierer, A. C., & Strangfeld, A. (2025). POS0506 NEW INCIDENT OR RECURRENT MALIGNANCIES IN PATIENT WITH RHEUMATOID ARTHRITIS AND A HISTORY OF MALIGNANCY IN ROUTINE CARE. Annals of the Rheumatic Diseases, 84, 722. https://doi.org/10.1016/j.ard.2025.05.888
How many times has this paper been cited?
0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.
Who wrote this paper?
M. Schaefer, H. Wernitzsch, N. Blank, B. Müller, Bernhard Manger, Anne C. Regierer, Anja Strangfeld.
What is the DOI of this paper?
10.1016/j.ard.2025.05.888, permanently at https://doi.org/10.1016/j.ard.2025.05.888. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.